Evaluation of Acebilustat, a Selective Inhibitor of Leukotriene B4 Biosynthesis, for Treatment of Outpatients With Mild-Moderate Coronavirus Disease 2019: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
- 30 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (2), 186-193
- https://doi.org/10.1093/cid/ciad187
Abstract
The vast majority of COVID-19 disease occurs in outpatients where treatment is limited to anti-virals for high-risk subgroups. Acebilustat, a leukotriene B4 (LTB4) inhibitor, has potential to reduce inflammation and symptom duration. In a single-center trial spanning Delta and Omicron variants, outpatients were randomized to 100 mg of oral acebilustat or placebo for 28 days. Patients reported daily symptoms via electronic query through Day 28 with phone follow-up on Day 120 and collected nasal swabs on Days 1-10. The primary outcome was sustained symptom resolution to Day 28. Secondary 28-day outcomes included time to first symptom resolution, area under the curve (AUC) of longitudinal daily symptom scores; duration of viral shedding through Day 10; and symptoms on Day 120. Sixty participants were randomized to each study arm. At enrollment, median duration and number of symptoms were 4 (IQR 3-5) days and 9 (IQR 7-11) symptoms. Most patients (90%) were vaccinated with 73% having neutralizing antibodies. A minority (44%) of participants (35% in the acebilustat arm and 53% in placebo) had sustained symptom resolution at Day 28 (HR 0.6, 95% CI 0.34-1.04, p = 0.07 favoring placebo). There was no difference in mean AUC of symptom scores over 28 days (difference in mean of AUC 9.4, 95% CI -42.1-60.9, p=0.72). Acebilustat did not impact viral shedding or symptoms at Day 120. Sustained symptoms through Day 28 were common in this low-risk population. Despite this, LTB4 antagonism with acebilustat did not shorten symptom duration in outpatients with COVID-19.Funding Information
- Stanford University
- Celltaxis
- CTSA (UL1 TR003142)
- NIH
This publication has 38 references indexed in Scilit:
- Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic FibrosisClinical and Translational Science, 2016
- Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A InductionClinical and Translational Science, 2016
- Circulating Leukotriene B4 Identifies Respiratory Complications after TraumaMediators of Inflammation, 2012
- Lipoxygenase and Leukotriene Pathways: Biochemistry, Biology, and Roles in DiseaseChemical Reviews, 2011
- Leukotriene B4 Mediates Neutrophil Migration Induced by HemeThe Journal of Immunology, 2011
- Randomization by minimization for unbalanced treatment allocationStatistics in Medicine, 2009
- LeukotrienesThe New England Journal of Medicine, 2007
- Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissuesNature Immunology, 2003
- Increased Concentrations of Leukotrienes in Bronchoalveolar Lavage Fluid of Patients with ARDS or At Risk for ARDSAmerican Review of Respiratory Disease, 1988
- Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytesNature, 1980